1ANELLO C,O’NEILL RT,DUBEY S.Multicentre trials:a US regulatory perspective[J].Stat Methods Med Res,2005,14(3):303-318.
2Anon.Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products.CPMP working party on efficacy of medicinal products note for guidance Ⅲ/3630/92-EN[J].Stat Med,1995,14(15):1659-1682.
3Center for Drug Evaluation and Research,Food and Drug Administration,U.S.Department of Health and Human Services.‘Documentation of statistical methods’,Guideline For The Format and Content of the Clinical and Statistical Sections of New Drug Applications[J/OL].[1988-06-05].http://www.fda.gov/cder/guidance/statnda.pdf.
4U.S.Department of Health and Human Services,Food and Drug Administration,Center for Drug Evaluation and Research(CDER),et al.‘Evidence of Effectiveness from a Single Study’,Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products[J/OL].[1988-05-31].http://www.fda.gov/cber/guidelines.htm.
5WORTHINGT ON H.Methods for pooling results from multicenter studies[J].J Dent Res,2004,83:C119-C121.
6LIN Z.An issue of statistical analysis in controlled multi-centre studies:how shall we weight the centres?[J].Stat Med,1999,18(4):365-373.
7SENN S.Some controversies in planning and analysing multicentre trials[J].Stat Med,1998,17(15-16):1753-1765.
8SAS Institute Inc.SAS/STAT誖9.2 User’s Guide:The Four Types of Estimable Functions[M].Cary,NC:SAS Institute Inc,2008:2-17.
9FLEISS J.Analysis of data from multiclinic trials[J].Control Clin Trials,1986,7(4):267-275.
10DMITRIENKO A,MOLENBERGHS G,CHRISTY CS,et al.Analysis of clinical trials using SAS:a practical guide[M].Cary,NC:SAS Institute Inc,2005:3-19.
